Ivermectin vs. Metronidazole for Rosacea [2026]: Which Prescription Treatment Is Better?
Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. Our editorial opinions are our own.
Topical ivermectin 1% is clinically superior to topical metronidazole for treating moderate-to-severe papulopustular rosacea. In randomized clinical trials, once-daily ivermectin achieved an 83% reduction in inflammatory lesions compared to 73.7% for twice-daily metronidazole, while offering longer symptom-free remission. However, metronidazole remains an affordable, gentle anti-inflammatory cornerstone for mild cases.
Affiliate Disclosure: PrescribedGlow is supported by our readers. When you purchase prescription treatments through links on our site, we may earn an affiliate commission at no extra cost to you.
| Clinical Feature | Topical Ivermectin (Soolantra) | Topical Metronidazole (MetroGel) |
|---|---|---|
| Drug Classification | Antiparasitic & anti-inflammatory avermectin | Synthetic nitroimidazole anti-inflammatory |
| Primary Mechanism | Eradicates Demodex mites & inhibits inflammatory cytokines | Scavenges reactive oxygen species & inhibits neutrophil burst |
| Available Strengths | 1.0% cream | 0.75% (gel, cream, lotion) and 1.0% (gel, cream) |
| Dosing Frequency | Once daily (at night) | Once daily (1%) or twice daily (0.75%) |
| Lesion Reduction (16 Weeks) | 83.0% mean reduction (ATTRACT study) | 73.7% mean reduction (ATTRACT study) |
| Investigator Success (Clear/Almost Clear) | 84.9% of subjects | 75.4% of subjects |
| Median Time to First Relapse | 115 days | 85 days |
| Retail Pharmacy Cash Price | $500–$650 (Soolantra) / $60–$120 (generic) | $15–$35 (generic 45g tube) |
| Telehealth Monthly Cost | $29.95–$36/month (compounded) | $29.95–$35/month (compounded or generic) |
| Best Clinical Fit | Moderate-to-severe papules, pustules, high Demodex load | Mild-to-moderate erythema, sensitive skin, budget priority |
What is the difference between ivermectin and metronidazole for rosacea?
The fundamental difference between ivermectin and metronidazole is their biological mechanism of action. Ivermectin acts as both an antiparasitic and anti-inflammatory agent, specifically killing microscopic Demodex mites and reducing cytokine release. Metronidazole acts primarily as an antioxidant and anti-inflammatory agent, neutralizing reactive oxygen species without killing follicular mites.
Papulopustular rosacea is characterized by sensitive facial redness accompanied by inflamed papules and pustules. While both medications soothe inflammatory pathways, their cellular targets diverge significantly:
- Ivermectin: Belongs to the avermectin class. It causes neuromuscular paralysis in Demodex mites by opening glutamate-gated chloride channels. Simultaneously, it downregulates inflammatory cytokines including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), and cathelicidin LL-37.
- Metronidazole: A synthetic nitroimidazole that reduces free-radical tissue damage by inhibiting neutrophil oxidative burst. It calms vascular irritation and reduces superficial papule counts, but it exerts no direct antiparasitic effect against facial mites.
This biological distinction matters because follicular parasites play a documented role in rosacea pathogenesis. In a quantitative meta-analysis published in the Journal of the European Academy of Dermatology and Venereology (Zhao et al., 2012; PMID: 22171688), patients with rosacea exhibited an overwhelmingly higher Demodex mite density than healthy controls (odds ratio of 5.7), with significantly greater mite prevalence among papulopustular patients. By eradicating these microscopic irritants, ivermectin resolves a core trigger that metronidazole leaves untreated.
Is ivermectin more effective than metronidazole for rosacea?
Yes, rigorous head-to-head clinical trials demonstrate that topical ivermectin 1% cream provides superior lesion clearance and faster symptom relief than topical metronidazole. Patients treated with once-daily ivermectin clear significantly more inflammatory bumps than those applying twice-daily metronidazole, while maintaining their remission for longer periods after stopping therapy.
The definitive head-to-head trial comparing both topicals is the multicenter Phase 3 ATTRACT study, published in the British Journal of Dermatology (Taieb et al., 2015; PMID: 25228137). In this randomized, investigator-blinded trial involving 962 subjects with moderate-to-severe papulopustular rosacea:
- Higher Lesion Reduction: At week 16, once-daily ivermectin 1% achieved an 83.0% mean reduction in inflammatory lesions, compared to 73.7% for twice-daily metronidazole 0.75% ($p < 0.001$).
- Superior Investigator Success: 84.9% of patients in the ivermectin group achieved “clear” or “almost clear” skin on the Investigator’s Global Assessment (IGA), versus 75.4% in the metronidazole group ($p = 0.001$).
- Earlier Clinical Clearance: Statistically significant superiority for ivermectin was observed as early as week 3, demonstrating faster onset of action despite applying it only once per day.
The clinical advantage of ivermectin extends beyond initial clearing to long-term disease management. In a 36-week extension of the ATTRACT study published in the Journal of the European Academy of Dermatology and Venereology (Taieb et al., 2016; PMID: 26691278), researchers monitored patients who had achieved clinical success after cessation of active treatment.
The median time to first relapse was 115 days for patients originally treated with ivermectin, compared to 85 days for those treated with metronidazole ($p = 0.0365$). Furthermore, the relapse rate was lower in the ivermectin cohort (62.7% vs. 68.4%), confirming that clearing follicular mite populations produces longer-lasting stability before symptoms recur.
These single-trial findings are confirmed by larger meta-analyses. A comprehensive network meta-analysis published in SpringerPlus (Siddiqui et al., 2016; PMID: 27504249) evaluated all available topical treatments for rosacea. The researchers concluded that once-daily ivermectin 1% cream had a significantly higher probability of achieving treatment success than twice-daily metronidazole 0.75% cream and twice-daily azelaic acid 15% gel, while maintaining equivalent cutaneous safety.
Can you use ivermectin and metronidazole together?
Yes, you can safely use ivermectin and metronidazole together. Because the two medications do not interact negatively and utilize distinct biochemical pathways to suppress rosacea flares, dermatologists frequently combine them to achieve multi-modal symptom control for resistant or severe cases.
When prescribed as separate commercial tubes, providers typically recommend applying metronidazole in the morning to provide daytime antioxidant coverage and ivermectin at night. Metronidazole’s lightweight gel or lotion absorbs quickly under sunscreen and makeup, while ivermectin cream delivers soothing hydration overnight during peak mite activity.
In recent years, digital dermatology compounding pharmacies have streamlined this approach by combining both actives into a single nightly prescription. Leading telehealth platforms now compound custom “triple rosacea creams” containing:
- Ivermectin (1.0%): Clears Demodex mites and dampens tissue inflammation.
- Metronidazole (1.0%): Neutralizes reactive oxygen species and calms capillary hypersensitivity.
- Azelaic Acid (10%–15%): Unclogs follicular channels and lightens residual red marks. (Read our azelaic acid vs tretinoin guide to learn how azelaic acid compares to retinoids).
Combining these complementary ingredients into one bottle simplifies patient adherence, avoids layering heavy product bases, and targets rosacea across three independent pathways.
What are the side effects of ivermectin vs metronidazole?
Both topical ivermectin and metronidazole exhibit excellent safety records, with adverse reactions documented in fewer than 3% of clinical trial participants. Neither medication causes the intense peeling, skin barrier breakdown, or retinoid dermatitis associated with anti-aging treatments like tretinoin. However, their localized side effect patterns differ slightly during the initial weeks of treatment.
Metronidazole is known for being exceptionally gentle on fragile complexions. Its potential side effects are limited to mild, transient skin dryness, occasional stinging upon application, and minor peeling. Choosing an emollient cream base rather than an alcohol-free gel generally mitigates dryness for sensitive skin types.
Ivermectin is formulated in a moisturizing cetyl alcohol base that is well-tolerated by barrier-compromised skin. However, some patients experience a distinctive “die-off” phenomenon during the first 10 to 14 days of use. As ivermectin rapidly paralyzes large numbers of follicular Demodex mites, the release of parasitic antigens and associated Bacillus oleronius bacteria can trigger a temporary spike in facial redness, itching, or tiny white bumps. This initial flare typically resolves within two weeks, giving way to significant skin clearing.
Neither topical drug enters the bloodstream in meaningful concentrations. In pharmacokinetic analyses, systemic absorption of topical metronidazole is less than 1% of an equivalent oral dose, and plasma concentrations of topical ivermectin remain negligible, minimizing risk of systemic drug interactions.
How much do ivermectin and metronidazole cost online?
Metronidazole is substantially cheaper than ivermectin when purchasing brand-name commercial products at retail pharmacies, but telehealth compounding services bridge this price gap by offering custom blended formulas at flat subscription rates.
At traditional brick-and-mortar pharmacies, brand-name Soolantra (ivermectin 1% cream) is notoriously expensive, often costing $500 to $650 per 45g tube without health insurance. While generic ivermectin 1% cream has entered retail distribution, it still ranges from $60 to $120 per tube with pharmacy discount coupons. In contrast, generic metronidazole (0.75% or 1%) has been off-patent for decades, making it one of the most affordable dermatological prescriptions available at $15 to $35 per tube.
| Provider / Service | Formulation Type | Monthly Cost | Consultation Fee | Insurance Accepted? |
|---|---|---|---|---|
| Retail Pharmacy (Generic Metronidazole) | Standalone generic 0.75% or 1% tube | $15–$35 | In-person copay ($50–$200+) | Yes |
| Retail Pharmacy (Soolantra / Generic Ivermectin) | Standalone generic 1% tube | $60–$120 | In-person copay ($50–$200+) | Yes (often requires prior auth) |
| Dermatica | Custom compounded (Ivermectin + Metronidazole + Azelaic) | $22.42–$29.95/month | $4.99 one-time | No (HSA/FSA eligible) |
| Ro Derm | Custom compounded rosacea formula | $35–$44/month | $0 (Free online visit) | No (HSA/FSA eligible) |
| Curology | Custom rosacea formula (Metronidazole + Azelaic) | $29.95/month | $0 ($5.45 shipping trial) | No (HSA/FSA eligible) |
| Musely | The Red Rescue custom cream | $36/month ($72/2-month supply) | $20 one-time | No (HSA/FSA eligible) |
| Nurx | Standard generic topicals & Soolantra | Copay ($0–$15) or $30–$90 cash | $40 one-time | Yes (bills insurance for Rx) |
For patients without robust prescription drug insurance, online telehealth platforms offer superior economic value. Dermatica compounds prescription ivermectin and metronidazole together for $29.95 per month (billed bimonthly at $59.90, with prepaid options as low as $22.42 per month). Ro Derm offers customized anti-inflammatory rosacea topicals starting at $35 to $44 per month with no medical consultation fees. If you prefer utilizing your existing health insurance for standard generics, Nurx processes commercial plans directly. To understand the full telemedicine intake workflow, review our guide on how online telehealth skincare works.
Frequently asked questions
Is ivermectin better than metronidazole for rosacea? Yes, multiple clinical trials demonstrate that once-daily ivermectin 1% cream is superior to metronidazole in clearing rosacea bumps and pustules. In the landmark ATTRACT trial, ivermectin achieved an 83% lesion reduction at 16 weeks compared to 73.7% for metronidazole, with significantly longer symptom-free remission.
Can you use ivermectin and metronidazole together? Yes, dermatologists and telehealth compounding pharmacies frequently combine ivermectin and metronidazole. Because they utilize distinct mechanisms—ivermectin targets Demodex mites and inflammation while metronidazole acts as an antioxidant—using them together or alternating morning and night provides enhanced symptom control without adverse interactions.
How long does it take for ivermectin and metronidazole to work? Both medications begin showing initial improvements in inflammatory lesions within 3 to 4 weeks. However, ivermectin demonstrates faster initial clearing by week 3 and reaches peak clinical clearance by week 12 to 16, whereas metronidazole typically reaches peak benefits between weeks 8 and 12.
What are the common side effects of ivermectin vs metronidazole? Both topicals have exceptionally low side effect rates (under 3% in clinical trials). Metronidazole occasionally causes mild skin dryness, stinging, or minor flaking. Ivermectin can cause transient burning or a temporary initial flare during the first two weeks as Demodex mites die off, followed by rapid improvement.
Why is brand Soolantra more expensive than metronidazole? Soolantra is a patented brand-name formulation of 1% ivermectin cream, costing upwards of $500 out-of-pocket at commercial retail pharmacies. Generic metronidazole 0.75% or 1% has been available for decades and costs $15 to $35. However, telehealth compounding pharmacies provide generic ivermectin for around $30 to $36 monthly.
Where can you get prescription ivermectin and metronidazole online? You can obtain prescription ivermectin and metronidazole through telehealth dermatology platforms like Dermatica, Ro Derm, Curology, and Musely. After a licensed clinician reviews your facial photos and health history, they prescribe standalone topicals or customized multi-ingredient creams shipped directly to your home.
Bottom line
Topical ivermectin 1% is the overall winner for moderate-to-severe papulopustular rosacea. Backed by the multicenter ATTRACT trial, it provides superior inflammatory lesion clearance (83.0% vs. 73.7%), works faster by week 3, and keeps skin in remission for 115 days compared to 85 days for metronidazole. Its ability to eradicate overabundant Demodex mites addresses a fundamental biological driver of the disease that other topicals leave untouched.
Topical metronidazole remains an excellent, budget-friendly baseline therapy for mild rosacea and patients with reactive, sensitive complexions who cannot tolerate avermectin die-off. However, for maximum therapeutic efficacy without retail pharmacy markup, custom compounding that unites both actives in a single bottle offers the ideal clinical path forward.
Try Custom Rosacea Cream at Dermatica → · Read our Dermatica review → · Try Ro Derm Rosacea Treatment → · Read our Ro Derm review → · Rosacea Treatment Hub → · Metronidazole for Rosacea Guide →
Sources
- Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, Jacovella J. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. British Journal of Dermatology. 2015;172(4):1103-1110. PMID: 25228137. https://pubmed.ncbi.nlm.nih.gov/25228137/
- Taieb A, Khemis A, Ruzicka T, Barańska-Rybak W, Berth-Jones J, Schauber J, Briantais P, Jacovella J, Passeron T. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study. Journal of the European Academy of Dermatology and Venereology. 2016;30(5):829-836. PMID: 26691278. https://pubmed.ncbi.nlm.nih.gov/26691278/
- Siddiqui K, Stein Gold L, Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. SpringerPlus. 2016;5(1):1151. PMID: 27504249. https://pubmed.ncbi.nlm.nih.gov/27504249/
- van Zuuren EJ, Fedorowicz Z, Tan J, et al. Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments. British Journal of Dermatology. 2019;181(1):65-79. PMID: 30585305. https://pubmed.ncbi.nlm.nih.gov/30585305/
- Zhao YE, Wu LP, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Journal of the European Academy of Dermatology and Venereology. 2012;26(6):796-802. PMID: 22171688. https://pubmed.ncbi.nlm.nih.gov/22171688/